FitMi AD for Alzheimer's Disease

Phase-Based Progress Estimates
Rancho Research Institute, Inc, Downey, CA
Alzheimer's Disease+3 More
FitMi AD - Device
All Sexes
What conditions do you have?

Study Summary

This study will investigate the efficacy of a newly developed exercise device (FitMi AD) for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. FitMi AD uses embedded sensors that can track and record the patient's direction and degree of movement while performing exercises described on a computer.

Eligible Conditions

  • Alzheimer's Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Alzheimer's Disease

Study Objectives

3 Primary · 5 Secondary · Reporting Duration: Immediately Post-Treatment (an average of 3 months)

Month 3
Change in 30 second chair stand test
Change in Functional Reach Test
Change in Timed Up and Go test
Geriatric Depression Scale
Global Physical Activity Questionnaire
Pittsburgh Sleep Quality Index
Visual Analog Pain Scale
Month 3
Duration of exercise performed

Trial Safety

Safety Progress

1 of 3

Other trials for Alzheimer's Disease

Trial Design

2 Treatment Groups

Active Comparator: Conventional booklet of exercise program
1 of 2
Experimental: FitMi AD Exercise Program
1 of 2
Active Control
Experimental Treatment

30 Total Participants · 2 Treatment Groups

Primary Treatment: FitMi AD · No Placebo Group · Phase 1

Experimental: FitMi AD Exercise Program
Experimental Group · 1 Intervention: FitMi AD · Intervention Types: Device
Active Comparator: Conventional booklet of exercise program
ActiveComparator Group · 1 Intervention: Conventional exercise program · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: immediately post-treatment (an average of 3 months)
Closest Location: Rancho Research Institute, Inc · Downey, CA
Photo of california 1Photo of california 2Photo of california 3
N/AFirst Recorded Clinical Trial
0 TrialsResearching Alzheimer's Disease
0 CompletedClinical Trials

Who is running the clinical trial?

Flint Rehabilitation Devices, LLCLead Sponsor
3 Previous Clinical Trials
87 Total Patients Enrolled
Rancho Research Institute, Inc.OTHER
6 Previous Clinical Trials
423 Total Patients Enrolled
Freddi Segal-Gidan, PA, PhDPrincipal InvestigatorRancho Research Institute, Inc.

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have MCI or mild dementia due to AD.
You are able to clearly see the screen and hear the audio instructions from the tablet.
You have a family member or friend who can answer questions about your daily living skills.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.